End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- JOD | -.--% | -.--% | -.--% |
25/02 | Birzeit Pharmaceuticals Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
09/01 | What does the Gotham City report say about Grifols? | RE |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicines
100.0
%
| 47 | 100.0 % | 43 | 100.0 % | -8.31% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Palestine
100.0
%
| 47 | 100.0 % | 43 | 100.0 % | -8.31% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Talal Nasereddin
CEO | Chief Executive Officer | 74 | 01/84/01 |
Director of Finance/CFO | - | 15/84/15 | |
Chief Tech/Sci/R&D Officer | - | 01/97/01 | |
Chief Tech/Sci/R&D Officer | 71 | 03/77/03 | |
Chief Administrative Officer | 54 | 01/92/01 | |
Comptroller/Controller/Auditor | - | 09/98/09 | |
Human Resources Officer | - | 06/09/06 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 01/21/01 | |
Chief Administrative Officer | 54 | 01/92/01 | |
Talal Nasereddin
CEO | Chief Executive Officer | 74 | 01/84/01 |
Director/Board Member | - | 30/84/30 | |
Director/Board Member | - | 30/90/30 | |
Director/Board Member | - | 28/92/28 | |
Director/Board Member | - | 18/11/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 38,764,898 | 28,654,287 ( 73.92 %) | 0 | 73.92 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+15.91% | 4.2TCr | |
+22.40% | 2.23TCr | |
+18.48% | 1.52TCr | |
+16.12% | 1.4TCr | |
+45.12% | 1.21TCr | |
-9.58% | 679.6Cr | |
-0.05% | 678.76Cr | |
-8.87% | 572.55Cr | |
+14.18% | 549.33Cr |
- Stock Market
- Equities
- BPC Stock
- Stock
- Company Birzeit Pharmaceuticals Company